ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?

Bladder cancer therapy relies on aggressive treatments highlighting the need for new, targeted therapies with reduced side effects. SWI/SNF complexes are mutated in ~20% across human cancers and dependency of SWI/SNF-deficient tumors on EZH2 has been uncovered recently. To systematically dissect the...

Descripción completa

Detalles Bibliográficos
Autores principales: Garczyk, Stefan, Schneider, Ursula, Lurje, Isabella, Becker, Katharina, Vögeli, Thomas A., Gaisa, Nadine T., Knüchel, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107234/
https://www.ncbi.nlm.nih.gov/pubmed/30138427
http://dx.doi.org/10.1371/journal.pone.0202965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107234/
https://www.ncbi.nlm.nih.gov/pubmed/30138427
http://dx.doi.org/10.1371/journal.pone.0202965

Ejemplares similares